• Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
    Tjon Pian Gi RE, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, Hantzakos A, Lawson G, Remacle M, Rihkanen H, Dikkers FG.
    Eur Arch Otorhinolaryngol. 2012 Feb;269(2):361-2.

 

  • Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Tjon Pian Gi RE, Ilmarinen T, van den Heuvel ER, Aaltonen LM, Andersen J, Brunings JW, Chirila M, Dietz A, Ferran Vilà F, Friedrich G, de Gier HH, Golusinski W, Graupp M, Hantzakos A, Horcasitas R, Jackowska J, Koelmel JC, Lawson G, Lindner F, Remacle M, Sittel C, Weichbold V, Wierzbicka M, Dikkers FG.
    Eur Arch Otorhinolaryngol. 2013 May;270(5):1679-87.

 

  • Age of onset of recurrent respiratory papillomatosis: a distribution analysis.
    San Giorgi MR, van den Heuvel ER, Tjon Pian Gi RE, Brunings JW, Chirila M, Friedrich G, Golusinski W, Graupp M, Horcasitas Pous RA, Ilmarinen T, Jackowska J, Koelmel JC, Ferran Vilà F, Weichbold V, Wierzbicka M, Dikkers FG.
    Clin Otolaryngol. 2016 Oct;41(5):448-53.